These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36584099)

  • 21. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Favipiravir for symptomatic COVID-19: A nationwide observational cohort study.
    Doi Y; Ishihara T; Banno S; Ando M; Kondo M;
    J Infect Chemother; 2023 Feb; 29(2):150-156. PubMed ID: 36307058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of risk factors for uric acid elevation in COVID-19 patients treated with favipiravir.
    Hanai Y; Yoshizawa S; Matsuo K; Uekusa S; Miyazaki T; Nishimura K; Mabuchi T; Ohashi H; Ishii Y; Tateda K; Yoshio T; Nishizawa K
    Diagn Microbiol Infect Dis; 2022 Apr; 102(4):115640. PubMed ID: 35193798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
    Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M;
    Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial.
    Shinkai M; Tsushima K; Tanaka S; Hagiwara E; Tarumoto N; Kawada I; Hirai Y; Fujiwara S; Komase Y; Saraya T; Koh H; Kagiyama N; Shimada M; Kanou D; Antoku S; Uchida Y; Tokue Y; Takamori M; Gon Y; Ie K; Yamazaki Y; Harada K; Miyao N; Naka T; Iwata M; Nakagawa A; Hiyama K; Ogawa Y; Shinoda M; Ota S; Hirouchi T; Terada J; Kawano S; Ogura T; Sakurai T; Matsumoto Y; Kunishima H; Kobayashi O; Iwata S
    Infect Dis Ther; 2021 Dec; 10(4):2489-2509. PubMed ID: 34453234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial.
    Golan Y; Campos JAS; Woolson R; Cilla D; Hanabergh R; Gonzales-Rojas Y; Lopez R; Finberg R; Balboni A
    Clin Infect Dis; 2023 Feb; 76(3):e10-e17. PubMed ID: 36065065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes in COVID-19 patients treated with antivirals: a retrospective analysis.
    Jain J; Chandak D; Basak S
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Assessment of the Efficacy and Safety of Favipiravir for Patients with SARS-CoV-2 Infection: A Multicenter Non-randomized, Uncontrolled Single-arm Prospective Study.
    Yanagisawa K; Takara K; Suga H; Saito A; Hayashi T; Igarashi T; Tomizawa S; Saito E; Sumiyoshi H; Ohyama Y; Tokue Y; Nakamura T
    Intern Med; 2022 Nov; 61(21):3197-3204. PubMed ID: 35945028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
    Surapat B; Kobpetchyok W; Kiertiburanakul S; Arnuntasupakul V
    Int J Clin Pract; 2022; 2022():3098527. PubMed ID: 35685498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
    Tsuboi H; Kasamatsu Y; Matsubara S; Sasao A; Kunimitsu K; Munakata N; Ito T; Tsuchido Y; Yamawaki M; Fujita N
    J Infect Chemother; 2021 Jul; 27(7):1072-1075. PubMed ID: 33814353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of and risk factors for depression, anxiety, and stress in non-hospitalized asymptomatic and mild COVID-19 patients in East Java province, Indonesia.
    Lusida MAP; Salamah S; Jonatan M; Wiyogo IO; Asyari CH; Ali ND; Asmara J; Wahyuningtyas RI; Triyono EA; Ratnadewi NK; Irzaldy A; Alkaff FF
    PLoS One; 2022; 17(7):e0270966. PubMed ID: 35797394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of favipiravir versus hydroxychloroquine on clinical and laboratory findings in COVID-19 in healthcare workers.
    Turan DB; Menteş M; Özel Y; Şerefhanoğlu K; Aydoğan B; İbil N; Güneşdoğdu F; Orucova HM; Saltürk C; Çelik H
    Braz J Infect Dis; 2022; 26(1):102328. PubMed ID: 35139366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mood, Anxiety and Olfactory Dysfunction in COVID-19: Evidence of Central Nervous System Involvement?
    Speth MM; Singer-Cornelius T; Oberle M; Gengler I; Brockmeier SJ; Sedaghat AR
    Laryngoscope; 2020 Nov; 130(11):2520-2525. PubMed ID: 32617983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
    Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM
    Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.